title: Safety and tolerability of omalizumab.
abstract: BACKGROUND
  Omalizumab (Xolair) is a recombinant humanized monoclonal anti-IgE antibody with proven efficacy in patients with moderate-to-severe and severe persistent allergic (IgE-mediated) asthma.
  
  
  OBJECTIVE
  To review clinical study data to assess the safety profile of omalizumab.
  
  
  METHODS
  We analysed the safety of omalizumab using data from completed clinical studies (up to 1 year) involving more than 7500 patients with asthma, rhinitis or related conditions and up to 4 years in one study of patients with severe allergic asthma, as well as post-marketing safety data. Analysis focuses on the risk of immune-system effects, hypersensitivity reactions, malignant neoplasia, parasitic infections and thrombocytopenia.
  
  
  RESULTS
  Omalizumab exhibited a good safety and tolerability profile that was maintained up to 4 years in one study. The incidence of anaphylaxis was 0.14% in omalizumab-treated patients and 0.07% in control patients. No omalizumab-treated patient developed measurable anti-omalizumab antibodies. Post-marketing, based on estimated exposure of 57,300 patients (June 2003-December 2006), the frequency of anaphylaxis attributed to omalizumab use was estimated to be at least 0.2% of patients. Current clinical trial data do not support an increased risk of malignant neoplasia or thrombocytopenia with omalizumab.
  
  
  CONCLUSIONS
  Data indicate that the proven efficacy of add-on omalizumab in patients with moderate-to-severe or severe allergic asthma is accompanied by a favourable safety and tolerability profile.
authors.affiliation: Allergy Research Foundation, Los Angeles, CA 90025, USA. jcorren@ucla.edu
authors.forename: J
authors.initials: J
authors.lastname: Corren
authors.forename: T B
authors.initials: TB
authors.lastname: Casale
authors.forename: B
authors.initials: B
authors.lastname: Lanier
authors.forename: R
authors.initials: R
authors.lastname: Buhl
authors.forename: S
authors.initials: S
authors.lastname: Holgate
authors.forename: P
authors.initials: P
authors.lastname: Jimenez
mesh_terms: D000707:Anaphylaxis / Q000276:immunology; D018927:Anti-Asthmatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy*; D015267:Churg-Strauss Syndrome / Q000276:immunology; D002986:Clinical Trials as Topic; D006801:Humans; D007239:Infections / Q000276:immunology; D009369:Neoplasms / Q000276:immunology; D000069444:Omalizumab; D013921:Thrombocytopenia / Q000276:immunology
chemical_list: D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C026408:anti-IgE antibodies; D000069444:Omalizumab